Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CELU

Celularity Inc

Dec 13 • 04:00PM ET

2.22

Dollar change -0.08
Percentage change -3.48	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP EDIT FATE ADVM NTLA SAGE BLUE CARA SANA KPTI

| Held by: VTI VXF IWC DFAC DFSU

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.56	Insider Own	51.12%	Shs Outstand	21.98M	Perf Week	-5.93%
Market Cap	48.18M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	10.99M	Perf Month	-37.46%
Income	-35.05M	PEG	-	EPS next Q	-	Inst Own	11.09%	Short Float	6.44%	Perf Quarter	-20.43%
Sales	48.20M	P/S	1.00	EPS this Y	-	Inst Trans	0.93%	Short Ratio	0.66	Perf Half Y	-30.73%
Book/sh	0.79	P/B	2.82	EPS next Y	-	ROA	-24.51%	Short Interest	0.71M	Perf Year	10.72%
Cash/sh	0.01	P/C	370.64	EPS next 5Y	-	ROE	-147.50%	52W Range	1.30 - 7.97	Perf YTD	-10.27%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-718.48%	ROI	-80.15%	52W High	-72.15%	Beta	0.63
Dividend TTM	-	Quick Ratio	0.14	Sales past 5Y	12.07%	Gross Margin	46.89%	52W Low	70.77%	ATR (14)	0.45
Dividend Ex-Date	-	Current Ratio	0.19	EPS Y/Y TTM	84.64%	Oper. Margin	-82.83%	RSI (14)	45.76	Volatility	13.68% 23.34%
Employees	120	Debt/Eq	4.00	Sales Y/Y TTM	225.94%	Profit Margin	-72.72%	Recom	1.00	Target Price	25.00
Option/Short	Yes / Yes	LT Debt/Eq	1.53	EPS Q/Q	85.31%	Payout	-	Rel Volume	0.08	Prev Close	2.30
Sales Surprise	-42.97%	EPS Surprise	-70.83%	Sales Q/Q	145.54%	Earnings	-	Avg Volume	1.07M	Price	2.22
SMA20	-9.22%	SMA50	-7.51%	SMA200	-30.73%	Trades		Volume	89,908	Change	-3.48%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$5 → $1
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Jun-22-22	Initiated	H.C. Wainwright	Buy	$15
Apr-06-22	Downgrade	Truist	Buy → Hold	$10
Jan-28-22	Initiated	Oppenheimer	Outperform	$9
Nov-24-21	Initiated	Morgan Stanley	Equal-Weight	$9

Dec-10-24 08:00AM	Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter (GlobeNewswire)
Dec-06-24 08:00AM	Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023 (GlobeNewswire)
Nov-27-24 05:00PM	Celularity Inc. Announces Receipt of Nasdaq Notification (GlobeNewswire) -29.47%
Nov-20-24 08:30AM	Celularitys Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific (GlobeNewswire)
08:30AM	Celularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell and Regenerative Medicine Center in Asia Pacific (GlobeNewswire)
08:30AM	Loading…
Nov-18-24 08:30AM	Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter (GlobeNewswire) +12.60%
Nov-07-24 08:00AM	Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million (GlobeNewswire) +113.10%
Oct-23-24 08:30AM	Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel (GlobeNewswire) +7.06%
Oct-22-24 08:30AM	Celularity Provides Corporate Update (GlobeNewswire)
Oct-18-24 06:00PM	Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal (GlobeNewswire) -16.14%
Oct-16-24 05:15PM	Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound Product from Sequence LifeScience, Inc. (GlobeNewswire) -6.47%
Sep-05-24 04:05PM	Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference (GlobeNewswire)
Aug-28-24 04:45PM	Celularity Appoints Richard J. Berman to its Board of Directors (GlobeNewswire)
Aug-23-24 05:00PM	Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing (GlobeNewswire)
Jul-31-24 08:30AM	Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023 (GlobeNewswire) +5.35%
08:38AM	Loading…
Jun-03-24 08:38AM	Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-24-24 05:15PM	Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing (GlobeNewswire)
May-14-24 09:15AM	Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy (GlobeNewswire) +25.95%
Apr-22-24 08:00AM	Celularity Inc. to Host Investor and Analyst Research & Development Day (GlobeNewswire)
Apr-19-24 05:30PM	Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing (GlobeNewswire) -5.61%
Apr-18-24 04:30PM	Celularity Abstract Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials Accepted at ORS Tendon Conference 2024 (GlobeNewswire)
Apr-15-24 08:00AM	Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products (GlobeNewswire)
Apr-08-24 09:00AM	Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells (GlobeNewswire)
Mar-26-24 09:00AM	Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L (GlobeNewswire)
Mar-20-24 09:15AM	Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy (GlobeNewswire)
Mar-14-24 09:15AM	Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit (GlobeNewswire)
Mar-12-24 09:20AM	Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress (GlobeNewswire) -15.30%
Mar-07-24 09:35AM	Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells (GlobeNewswire) +27.67%
Feb-23-24 04:10PM	Celularity Announces 1-for-10 Reverse Stock Split (GlobeNewswire) +7.13% -9.56%
Feb-14-24 04:05PM	Celularity's Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease (GlobeNewswire)
09:00AM	Loading…
Feb-01-24 09:00AM	Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline (GlobeNewswire) +28.45%
Jan-25-24 09:00AM	Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions (GlobeNewswire) +16.00%
Jan-18-24 01:40PM	Celularity Releases CEO Letter to Shareholders (GlobeNewswire) +53.48%
Jan-04-24 01:00PM	Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare (GlobeNewswire) -9.25%
Jan-03-24 07:30PM	BioCellgraft Finalizes Commercialization Agreement with Celularity For The Manufacture and Distribution of Products for Therapeutic Use in Oral Healthcare (PR Newswire)
12:00PM	Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023 (GlobeNewswire)
Nov-24-23 01:15PM	Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing (GlobeNewswire)
Oct-18-23 09:00AM	Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification (GlobeNewswire) -8.35%
Sep-07-23 04:10PM	Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors (GlobeNewswire)
Aug-29-23 09:00AM	Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron (GlobeNewswire) +8.04%
Jul-27-23 09:07AM	Celularity Inc. Announces $3 Million Registered Direct Offering (GlobeNewswire) +9.57%
09:00AM	Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic Applications (GlobeNewswire)
Jul-18-23 09:00AM	Celularity Human Placental-Derived Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in Studies (GlobeNewswire) +5.71%
Jun-29-23 04:05PM	Celularity Announces Presentation at Upcoming 7th International Conference on Orthopedics (GlobeNewswire) +5.89%
Jun-01-23 09:15AM	Celularity Tissue Factor Gene Knockout of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance of Gene Editing Capability (GlobeNewswire) -8.71%
May-23-23 10:56AM	CELULARITY ANNOUNCES $45 MILLION PURCHASE ORDER, FIRST MIDDLE EAST PRIVATE LABEL AGREEMENT FOR CELULARITY'S HALAL-CERTIFIED BIOMATERIAL PRODUCTS (PR Newswire)
May-19-23 04:21PM	Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohns Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula Formation (GlobeNewswire) +11.27%
May-10-23 09:00AM	Celularity Announces Advisory Guidance From Tamer Group Regarding Anticipated 2023 Purchase Orders for Celularity Branded Halal-Certified Biomaterial Products (GlobeNewswire) +10.18%
May-01-23 04:01PM	Celularity Announces Acceptance of Presentation at 26th Annual Meeting of the American Society of Gene and Cell Therapy (GlobeNewswire) -8.79%
Apr-27-23 09:00AM	Celularity Announces Clinical Data on Human Placental-Derived Unmodified Allogeneic Natural Killer Cell Therapy Candidate Cynk-001 in Adult Patients With Relapsed Refractory and Measurable Residual Disease-Positive Acute Myeloid Leukemia (GlobeNewswire)
Apr-12-23 09:00AM	Celularitys Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference Beyond Longevity: Live 120 Like 50 (GlobeNewswire)
Apr-05-23 09:00AM	Celularity Inc. Announces $6 Million Registered Direct Offering (GlobeNewswire) -11.48%
Apr-04-23 09:00AM	Celularity Announces Acceptance of Poster Presentation at 2023 Society for Biomaterials Annual Meeting (GlobeNewswire)
Apr-03-23 09:00AM	Celularity Receives U.S. Food And Drug Administration (FDA) Preliminary Assessment For Celularitys Investigational Fuse Bone Void Filler To Be Regulated As A Device By FDAs Center For Devices And Radiological Health (GlobeNewswire) +19.41%
Mar-28-23 10:55AM	Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the GCC and Egypt (PR Newswire)
09:00AM	Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the Gulf Cooperation Council Regions and Egypt (GlobeNewswire)
Feb-02-23 07:53AM	Correcting & Replacing -- Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (CTW) to be Regulated as a Device Within U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) (GlobeNewswire)
Feb-01-23 04:05PM	Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (CTW) to be Regulated as a Device Within U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) (GlobeNewswire) +8.50%
Jan-26-23 04:17PM	Celularity Completes Strategic Review of 2023 Initiatives, Including Anticipated Biomaterials Production Ramp-Up and Pipeline Prioritization of Next-Generation Product Candidates (GlobeNewswire) +7.68%
Jan-11-23 01:35PM	Celularity and CH Trading Group Announce Territory Distribution Agreement for the Middle East (PR Newswire) +13.21%
01:22PM	Celularity and CH Trading Group Announce Product Distribution Agreement with Tamer Group to be the Exclusive Distributor for the Kingdom of Saudi Arabia (PR Newswire)
Jan-06-23 08:10AM	Celularitys Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohns Disease in Phase 1, Phase 1b/2a and Phase 1b Studies (GlobeNewswire)
Jan-04-23 04:10PM	Celularity Appoints Paul Graves as Chief Communications Officer (GlobeNewswire) -14.15%
Dec-05-22 08:00AM	Celularity Announces Halal Certification of its Advanced Cellular Therapeutics, Biomaterial Products and Business Model (Business Wire)
Nov-30-22 09:55AM	Celularity CEO Robert J. Hariri, M.D., Ph.D., Addresses FII Conference on "The Science and Technology for Extending Healthy Human Lifespan" (Business Wire)
Nov-10-22 05:00PM	Imugenes onCARlytics combination with Celularitys placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting (GlobeNewswire) +14.52%
04:10PM	Celularity Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
09:10AM	Celularity Presents Preclinical Data on CYNK-101, its Allogeneic Genetically-Modified Natural Killer Cell Therapy Candidate, at the Society for Immunotherapy of Cancers 37th Annual Meeting (GlobeNewswire)
Oct-06-22 08:00AM	Celularity Promotes Two Executives in Executive Leadership Team (GlobeNewswire)
Oct-03-22 08:00AM	Celularity Appoints Adrian Kilcoyne, M.D., M.P.H., M.B.A., as Chief Medical Officer (GlobeNewswire) -5.19%
Sep-27-22 08:00AM	Celularity to Present at Jefferies Cell and Genetic Medicine Summit (GlobeNewswire)
Sep-26-22 08:00AM	Celularity Publishes New Data in Frontiers in Immunology Demonstrating Placental-derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-infected Cells In Vitro (GlobeNewswire)
Sep-15-22 02:29PM	Celularity Enters Into $150 Million Pre-Paid Advance Agreement with Yorkville (GlobeNewswire) -8.90%
Sep-06-22 04:10PM	Celularity Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-09-22 04:10PM	Celularity Reports Second Quarter 2022 Financial Results and Corporate Update (GlobeNewswire)
Jul-27-22 08:00AM	Celularity Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Development for the First-Line Treatment of Advanced HER2 Positive Gastric and Gastroesophageal Junction (G/GEJ) Cancers (GlobeNewswire) -10.89%
Jul-04-22 10:08AM	Celularity (NASDAQ:CELU) shareholders have endured a 65% loss from investing in the stock a year ago (Simply Wall St.)
Jun-08-22 04:10PM	Celularity To Be Added To The Russell 3000® Index And The Small-Cap Russell 2000® (GlobeNewswire) -16.26%
Jun-03-22 08:00AM	Celularity Appoints Industry Leader Diane Parks to its Board of Directors (GlobeNewswire)
May-18-22 08:30AM	Celularity Inc. Announces $30 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
May-16-22 04:10PM	Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -12.53% +17.76%
Mar-31-22 04:05PM	Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-15-22 04:05PM	Celularity to Present at Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire)
12:59PM	What Percentage Of Celularity Inc. (NASDAQ:CELU) Shares Do Insiders Own? (Simply Wall St.)
Feb-15-22 04:05PM	Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers (GlobeNewswire) +8.36% +8.39%
Jan-27-22 05:38PM	C V Starr & Co Inc Buys Celularity Inc (GuruFocus.com) -6.47% +9.23%
05:38PM	Starr International Co Inc Buys Celularity Inc, Sells Moderna Inc, AstraZeneca PLC, Johnson ... (GuruFocus.com)
Jan-18-22 08:00AM	Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers (GlobeNewswire) -7.97%
Dec-27-21 08:00AM	Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML (GlobeNewswire) +6.60%
Dec-15-21 09:04AM	Analysts' Revenue Estimates For Celularity Inc. (NASDAQ:CELU) Are Surging Higher (Simply Wall St.)
Dec-13-21 08:00AM	Celularity Presents Preclinical Data on Allogeneic Genetically Modified Natural Killer (NK) and Allogeneic CAR-NK Cell Therapy Programs at the 63rd American Society of Hematology Meeting and Exposition (GlobeNewswire) -7.61%
Nov-29-21 08:00AM	Celularity Announces FDA Clearance of Investigational New Drug Application (IND) for Natural Killer Cell Therapy CYNK-101 in First-line Advanced Her2/neu Positive Gastric and Gastroesophageal Junction Cancer (GlobeNewswire)
Nov-16-21 05:35AM	Celularity (NASDAQ:CELU) investors are sitting on a loss of 34% if they invested a year ago (Simply Wall St.) +5.73%
Nov-15-21 08:00AM	Celularity Presents Preclinical Data on Allogeneic Genetically-Modified Natural Killer Cells at the Society for Immunotherapy of Cancer 36th Annual Meeting (GlobeNewswire)
Nov-12-21 04:05PM	Celularity Reports Third Quarter 2021 Financial Results and Corporate Update (GlobeNewswire)
Sep-20-21 08:00AM	Oncternal Therapeutics and Celularity Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies (GlobeNewswire)
08:00AM	Celularity and Oncternal Therapeutics Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies (GlobeNewswire)
Aug-16-21 05:15PM	Celularity Reports Second Quarter 2021 Financial Results (GlobeNewswire) -5.38% +11.38%
Aug-04-21 07:00PM	Imugene and Celularity Announce an Exclusive Strategic Partnership to Develop a Novel Oncolytic Virus - Allogeneic CAR T-Cell Immunotherapy Combination for the Treatment of Solid Tumors (GlobeNewswire) -7.73%

Celularity, Inc. is a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert Joseph Hariri Gordon in 2016 and is headquartered in Florham Park, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lim Kok Thay	10% Owner	Jan 12 '24	Buy	0.25	21,410,983	5,331,335	51,473,762	Jan 17 05:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CELU

Celularity Inc

Upgrade your FINVIZ experience